Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Debt / NOTE 3.500% 9/1
-
Unit price / market price
-
$1.95
-
Total 13F principal
-
$93,864,000
-
Principal change
-
-$45,085,000
-
Total reported value
-
$181,014,357
-
Number of holders
-
12
-
Value change
-
-$78,666,463
-
Number of buys
-
4
-
Number of sells
-
7
Institutional Holders of APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 as of Q3 2022
As of 30 Sep 2022 APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 had 12 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $93,864,000 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), LAZARD ASSET MANAGEMENT LLC, UBS ASSET MANAGEMENT AMERICAS INC, WOLVERINE ASSET MANAGEMENT LLC, WELLINGTON MANAGEMENT GROUP LLP, PALISADE CAPITAL MANAGEMENT LLC/NJ, JPMORGAN CHASE & CO, KORNITZER CAPITAL MANAGEMENT INC /KS, CITIGROUP INC, and MACKAY SHIELDS LLC.
This table shows 12 bond principal holders of the security as of 30 Sep 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.